Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In Vivo Theranostics at the Peri-Infarct Region in Cerebral Ischemia

  • Agulla, Jesús
  • Brea, David
  • Campos, Francisco
  • Sobrino, Tomás
  • Argibay, Bárbara
  • Al-Soufi, Wajih
  • Blanco, Miguel
  • Castillo, José
  • Ramos-Cabrer, Pedro
The use of theranostics in neurosciences has been rare to date because of the limitations imposed on the free delivery of substances to the brain by the blood-brain barrier. Here we report the development of a theranostic system for the treatment of stroke, a leading cause of death and disability in developed countries. We first performed a series of proteomic, immunoblotting and immunohistological studies to characterize the expression of molecular biomarkers for the so-called peri-infarct tissue, a key region of the brain for stroke treatment. We confirmed that the HSP72 protein is a suitable biomarker for the peri-infarct region, as it is selectively expressed by at-risk tissue for up to 7 days following cerebral ischemia. We also describe the development of anti-HSP72 vectorized stealth immunoliposomes containing imaging probes to make them traceable by conventional imaging techniques (fluorescence and MRI) that were used to encapsulate a therapeutic agent (citicoline) for the treatment of cerebral ischemia. We tested the molecular recognition capabilities of these nano-platforms in vitro together with their diagnostic and therapeutic properties in vivo, in an animal model of cerebral ischemia. Using MRI, we found that 80% of vectorized liposomes were located on the periphery of the ischemic lesion, and animals treated with citicoline encapsulated on these liposomes presented lesion volumes up to 30% smaller than animals treated with free (non-encapsulated) drugs. Our results show the potential of nanotechnology for the development of effective tools for the treatment of neurological diseases., Financial support from the Instituto de Salud Carlos III of the Spanish Ministry of Health (projects PI11/02161 and CP09/00074), the Spanish Ministry of Economy and Competence (projects SAF2008-02190, SAF2011-30517 and RETICS-INVICTUS R012/0014), and the European Union (FEDER program) is gratefully acknowledged. Research contracts from the Miguel Servet program (PRC and TS) and the Sara Borrell program (JA and DB) of the Instituto de Salud Carlos III are acknowledged., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study of protein expresion in peri-infarct tissue after cerebral ischemia

  • Brea, David
  • Agulla, Jesús
  • Staes, An
  • Gevaert, Kris|||0000-0002-4237-0283
  • Campos, Francisco|||0000-0001-8665-1039
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Blanco, Miguel
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Castillo, José
  • Ramos-Cabrer, Pedro|||0000-0003-0368-7031
In this work, we report our study of protein expression in rat peri-infarct tissue, 48 h after the induction of permanent focal cerebral ischemia. Two proteomic approaches, gel electrophoresis with mass spectrometry and combined fractional diagonal chromatography (COFRADIC), were performed using tissue samples from the periphery of the induced cerebral ischemic lesions, using tissue from the contra-lateral hemisphere as a control. Several protein spots (3408) were identified by gel electrophoresis, and 11 showed significant differences in expression between peri-infarct and contra-lateral tissues (at least 3-fold, p < 0.05). Using COFRADIC, 5412 proteins were identified, with 72 showing a difference in expression. Apart from blood-related proteins (such as serum albumin), both techniques showed that the 70 kDa family of heat shock proteins were highly expressed in the peri-infarct tissue. Further studies by 1D and 2D western blotting and immunohistochemistry revealed that only one member of this family (the inducible form, HSP72 or HSP70i) is specifically expressed by the peri-infarct tissue, while the majority of this family (the constitutive form, HSC70 or HSP70c) is expressed in the whole brain. Our data support that HSP72 is a suitable biomarker of peri-infarct tissue in the ischemic brain.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In Vivo Theranostics at the Peri-Infarct Region in Cerebral Ischemia

  • Agulla, Jesús
  • Brea, David
  • Campos, Francisco|||0000-0001-8665-1039
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Argibay, Bárbara
  • Al-Soufi, Wajih
  • Blanco, Miguel
  • Castillo, José
  • Ramos-Cabrer, Pedro|||0000-0003-0368-7031
The use of theranostics in neurosciences has been rare to date because of the limitations imposed on the free delivery of substances to the brain by the blood-brain barrier. Here we report the development of a theranostic system for the treatment of stroke, a leading cause of death and disability in developed countries. We first performed a series of proteomic, immunoblotting and immunohistological studies to characterize the expression of molecular biomarkers for the so-called peri-infarct tissue, a key region of the brain for stroke treatment. We confirmed that the HSP72 protein is a suitable biomarker for the peri-infarct region, as it is selectively expressed by at-risk tissue for up to 7 days following cerebral ischemia. We also describe the development of anti-HSP72 vectorized stealth immunoliposomes containing imaging probes to make them traceable by conventional imaging techniques (fluorescence and MRI) that were used to encapsulate a therapeutic agent (citicoline) for the treatment of cerebral ischemia. We tested the molecular recognition capabilities of these nano-platforms in vitro together with their diagnostic and therapeutic properties in vivo, in an animal model of cerebral ischemia. Using MRI, we found that 80% of vectorized liposomes were located on the periphery of the ischemic lesion, and animals treated with citicoline encapsulated on these liposomes presented lesion volumes up to 30% smaller than animals treated with free (non-encapsulated) drugs. Our results show the potential of nanotechnology for the development of effective tools for the treatment of neurological diseases.